glp 1 pancreatitis New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics Pancreatitis Warnings Strengthened on GLP-1RAs

Rizzo shared information on the ways Ozempic and other GLP-1 drugs might cause NAION and vision loss

While promising, robust clinical trials are needed to validate these claims

A temporary program is expected to: Provide limited coverage for GLP-1 medications used for obesity Apply only to certain eligible individuals Run for a short period (through the end of 2026) This is a step forward, but its not a permanent solution and will not apply to everyone

These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]

Complementary in vitro studies revealed that liraglutide exerted a dose-dependent inhibitory effect on the secretion of pro-inflammatory mediators, including interleukin 6 (IL-6), prostaglandin E2 (PGE2), and nitric oxide (NO), and suppressed the expression of inflammatory genes in chondrocytes and macrophages [45]